3-(Benzylthio)-Propionic acidCAS# 2899-66-3 |
2D Structure
- BAM7
Catalog No.:BCC1397
CAS No.:331244-89-4
- Bendamustine HCl
Catalog No.:BCC1153
CAS No.:3543-75-7
- Capsaicin
Catalog No.:BCN1016
CAS No.:404-86-4
- Betulinic acid
Catalog No.:BCN5524
CAS No.:472-15-1
- Brassinolide
Catalog No.:BCC1438
CAS No.:72962-43-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 2899-66-3 | SDF | Download SDF |
PubChem ID | 221428 | Appearance | Powder |
Formula | C10H12O2S | M.Wt | 196.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 3-benzylsulfanylpropanoic acid | ||
SMILES | C1=CC=C(C=C1)CSCCC(=O)O | ||
Standard InChIKey | NDBNSZKHDMXOJE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C10H12O2S/c11-10(12)6-7-13-8-9-4-2-1-3-5-9/h1-5H,6-8H2,(H,11,12) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
3-(Benzylthio)-Propionic acid Dilution Calculator
3-(Benzylthio)-Propionic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.0942 mL | 25.4712 mL | 50.9424 mL | 101.8849 mL | 127.3561 mL |
5 mM | 1.0188 mL | 5.0942 mL | 10.1885 mL | 20.377 mL | 25.4712 mL |
10 mM | 0.5094 mL | 2.5471 mL | 5.0942 mL | 10.1885 mL | 12.7356 mL |
50 mM | 0.1019 mL | 0.5094 mL | 1.0188 mL | 2.0377 mL | 2.5471 mL |
100 mM | 0.0509 mL | 0.2547 mL | 0.5094 mL | 1.0188 mL | 1.2736 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
3-(Benzylthio)-Propionic acid
- H-Methioninol
Catalog No.:BCC2721
CAS No.:2899-37-8
- H-Tryptophanol
Catalog No.:BCC2701
CAS No.:2899-29-8
- H-Trp-Oet.HCl
Catalog No.:BCC2673
CAS No.:2899-28-7
- Z-N-Me-Phe-OH
Catalog No.:BCC3349
CAS No.:2899-07-2
- Persicoside
Catalog No.:BCN4780
CAS No.:28978-03-2
- Pectolinarin
Catalog No.:BCN1217
CAS No.:28978-02-1
- CB 300919
Catalog No.:BCC1456
CAS No.:289715-28-2
- Boc-HomoArg(NO2)-OH
Catalog No.:BCC2646
CAS No.:28968-64-1
- Senicapoc
Catalog No.:BCC1943
CAS No.:289656-45-7
- Lasiodin
Catalog No.:BCN3387
CAS No.:28957-08-6
- Oridonin
Catalog No.:BCN5953
CAS No.:28957-04-2
- Cassiachromone
Catalog No.:BCN5192
CAS No.:28955-30-8
- TRAM-34
Catalog No.:BCC1122
CAS No.:289905-88-0
- Boc-Phg-OH
Catalog No.:BCC3311
CAS No.:2900-27-8
- Methyl reserpate
Catalog No.:BCN3489
CAS No.:2901-66-8
- Benzoyl-DL-valine
Catalog No.:BCC8864
CAS No.:2901-80-6
- Fmoc-Gly-OH
Catalog No.:BCC3498
CAS No.:29022-11-5
- 3-Epiglochidiol
Catalog No.:BCN5193
CAS No.:29028-10-2
- Daun02
Catalog No.:BCC1518
CAS No.:290304-24-4
- Glucosamine sulfate
Catalog No.:BCN5981
CAS No.:29031-19-4
- BMS 299897
Catalog No.:BCC2340
CAS No.:290315-45-6
- Bis(2-carboxyethyl)isocyanurate
Catalog No.:BCC8880
CAS No.:2904-40-7
- Matricin
Catalog No.:BCC8209
CAS No.:29041-35-8
- Hexanorcucurbitacin D
Catalog No.:BCN7875
CAS No.:29065-05-2
Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.[Pubmed:23838008]
Cell Signal. 2013 Nov;25(11):2147-54.
Lysophosphatidylethanolamine (LPE) is a lyso-type metabolite of phosphatidylethanolamine (a plasma membrane component), and its intracellular Ca(2+) ([Ca(2+)]i) increasing actions may be mediated through G-protein-coupled receptor (GPCR). However, GPCRs for lysophosphatidic acid (LPA), a structurally similar representative lipid mediator, have not been implicated in LPE-mediated activities in SK-OV3 or OVCAR-3 ovarian cancer cells or in receptor over-expression systems. In the present study, LPE-induced [Ca(2+)]i increase was observed in MDA-MB-231 cells but not in other breast cancer cell lines. In addition, LPE- and LPA-induced responses showed homologous and heterologous desensitization. Furthermore, VPC32183 and Ki16425 (antagonists of LPA1 and LPA3) inhibited LPE-induced [Ca(2+)]i increases, and knockdown of LPA1 by transfection with LPA1 siRNA completely inhibited LPE-induced [Ca(2+)]i increases. Furthermore, the involvement of CD97 (an adhesion GPCR) in the action of LPA1 in MDA-MB-231 cells was demonstrated by siRNA transfection. Pertussis toxin (a specific inhibitor of Gi/o proteins), edelfosine (an inhibitor of phospholipase C), or 2-APB (an inhibitor of IP3 receptor) completely inhibited LPE-induced [Ca(2+)]i increases, whereas HA130, an inhibitor of autotaxin/lysophospholipase D, did not. Therefore, LPE is supposed to act on LPA1-CD97/Gi/o proteins/phospholipase C/IP3/Ca(2+) rise in MDA-MB-231 breast cancer cells.